Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 16.6% in June

Jasper Therapeutics, Inc. (NASDAQ:JSPR) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 798,200 shares, a growth of 16.6% from the May 31st total of 684,800 shares. Currently, 7.3% of the company’s stock are sold short. Based on an average daily trading volume, of 85,900 shares, the short-interest ratio is presently 9.3 days.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on JSPR shares. Oppenheimer reaffirmed an “outperform” rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Royal Bank of Canada started coverage on Jasper Therapeutics in a research report on Thursday, March 28th. They set an “outperform” rating and a $70.00 price objective for the company. Stifel Nicolaus started coverage on Jasper Therapeutics in a research report on Thursday, June 27th. They set a “buy” rating and a $86.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Wednesday, May 15th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics has a consensus rating of “Buy” and a consensus target price of $67.00.

Institutional Trading of Jasper Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in shares of Jasper Therapeutics in the first quarter valued at approximately $306,000. Ikarian Capital LLC acquired a new stake in shares of Jasper Therapeutics in the first quarter valued at approximately $3,088,000. StemPoint Capital LP acquired a new stake in shares of Jasper Therapeutics in the first quarter valued at approximately $3,794,000. Russell Investments Group Ltd. acquired a new stake in shares of Jasper Therapeutics in the first quarter valued at approximately $2,343,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of Jasper Therapeutics in the first quarter valued at approximately $599,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR opened at $22.78 on Wednesday. The stock has a 50 day moving average price of $23.15 and a 200 day moving average price of $19.79. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01. The stock has a market capitalization of $343.07 million, a PE ratio of -4.05 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.23. As a group, research analysts forecast that Jasper Therapeutics will post -4.41 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.